FDA Commissioner Marty Makary breaks down Trump's executive order on psychedelics
President Trump signed an executive order directing federal agencies to advance psychedelic therapy research and development. FDA Commissioner Marty Makary discussed the order's implications and scope. The initiative represents a shift in federal drug policy toward potential therapeutic applications of psychedelic substances.
CBS News covered the FDA Commissioner's breakdown of the executive order, focusing on the administrative and regulatory dimensions of the policy shift.
Right-leaning outlets emphasized both the promise and practical limitations of Trump's psychedelic therapy order, exploring both its potential benefits and the challenges in implementation.
Key Differences
- Right-leaning sources provided dual analysis examining both opportunities and constraints, while left-leaning coverage focused on the commissioner's official explanation
- Center/independent outlets provided no coverage of this story, creating a notable gap in mainstream media attention
- Right-leaning outlets engaged in deeper policy analysis rather than simply reporting the announcement
Left(1)
Center(0)
Right(2)
ReasonAApr 20, 1:31 PM
Trump Signs Psychedelics Order
Plus: ship seizures, the best free bread in America, and more...
ReasonAApr 20, 7:40 PM
The Promise and Limits of Trump's Psychedelic Therapy Order
The president's facilitation of research and FDA review could help make psychedelics available to approved patients. But what about everyone else?
Get this analysis in your inbox
The Daily Spectrum: one email, three perspectives on the day's biggest stories.
Free forever. Unsubscribe anytime. No spam.